Rituxan (rituximab), a new monoclonal antibody for cancer

May 2000

Hoffmann-La Roche is now marketing Rituxan (rituximab), a new monoclonal antibody for cancer.

Rituxan is for certain cases of non-Hodgkin's lymphoma (NHL).

Rituxan binds to the malignant antibody-producing B-cells...this helps the immune system to recognize and eliminate them.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

NSAIDs contribute to congestive heart failure (CHF) in elderly patients
Women's Health whether hormone replacement therapy really does reduce the risk of heart disease
Women's Health Plan B, a new option for emergency contraception
Men's Health Uprima (you-PREE-ma), a new prescription alternative to Viagra
new dietary recommendations for antioxidants
Hematology & Oncology Rituxan (rituximab), a new monoclonal antibody for cancer
Gastroenterology alternative to Prepulsid (cisapride) for heartburn and other GI disorders
Osteoporosis Actonel (risedronate) for osteoporosis
Infectious Diseases penicillin TWICE DAILY for Strep throat
Infectious Diseases tricks to minimize the adverse CNS effects that patients get when they start Sustiva (efavirenz)
Infectious Diseases Zyvox (linezolid), a potent new antibiotic for certain drug-resistant gram-positive infections
Neurology & Pain suspect that some of the new antipsychotics might lead to diabetes
two new light-activated drugs
most drugs remain safe and effective long after their expiration date
Supplements vitamin C to help PREVENT the rare nerve disorder that occurs after an injury or fracture